sur Theranexus (EPA:ALTHX)
Theranexus, CRNL and CERMEP winners of the Auvergne-Rhône-Alpes “Research Pact 2024” project
Theranexus, a biopharmaceutical company treating rare neurological diseases, the Lyon Neurosciences Research Center (CRNL) and CERMEP have been selected for the “2024 Research Pact” project in the Auvergne-Rhône-Alpes region. The project, named IMASO, will benefit from regional funding of €320,000.
This support is a continuation of the joint public/private NI2D laboratory. Created in 2020 in Lyon, this laboratory aims to improve the characterization of Theranexus drug candidates using preclinical neuroimaging tools. The IMASO project will make it possible to measure in vivo the cerebral distribution of antisense oligonucleotides (ASO) developed by Theranexus.
Mathieu Charvériat, CEO of Theranexus, expressed his gratitude to the region for its financial support, essential for the preclinical and clinical development of ASOs in various rare neurological diseases. Luc Zimmer, director of CERMEP and the BIORAN team at CRNL, also underlined their satisfaction at continuing this fruitful collaboration.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theranexus